Ensysce Biosciences (ENSC) Net Income towards Common Stockholders (2018 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Net Income towards Common Stockholders of -$3.7 million for Q3 2025, down 663.51% year-over-year from $661769.0 in Q3 2024, and down 115.14% quarter-over-quarter from -$1.7 million in Q2 2025.
Ensysce Biosciences (ENSC) Net Income towards Common Stockholders (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Net Income towards Common Stockholders for 8 consecutive years, with -$3.7 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Net Income towards Common Stockholders fell 663.51% year-over-year to -$3.7 million; the TTM figure through Dec 2025 stood at -$7.4 million (up 7.25% YoY), while the FY2024 annual figure was -$8.0 million, up 24.83% from the prior year.
- Net Income towards Common Stockholders retreated to -$3.7 million in Q3 2025 per ENSC's latest filing, from -$1.7 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $661769.0 in Q3 2024 and bottomed at -$17.2 million in Q3 2021.
- Historically, Net Income towards Common Stockholders has averaged -$4.3 million across 5 years, with a median of -$2.7 million in 2023.
- Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders slumped 5165.56% — and 2024, when it jumped 124.61%.
- Ensysce Biosciences' Net Income towards Common Stockholders stood at -$10.8 million in 2021, then soared by 49.06% to -$5.5 million in 2022, then surged by 36.54% to -$3.5 million in 2023, then declined by 1.72% to -$3.6 million in 2024, then decreased by 4.62% to -$3.7 million in 2025.
- Business Quant data shows ENSC's Net Income towards Common Stockholders at -$3.7 million in Q3 2025, -$1.7 million in Q2 2025, and -$1.9 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -3.73 Mn |
| Jun 30, 2025 | -1.73 Mn |
| Mar 31, 2025 | -1.95 Mn |
| Dec 31, 2024 | -3.56 Mn |
| Sep 30, 2024 | 661,769.00 |
| Jun 30, 2024 | -1.97 Mn |
| Mar 31, 2024 | -3.12 Mn |
| Dec 31, 2023 | -3.50 Mn |
| Sep 30, 2023 | -2.69 Mn |
| Jun 30, 2023 | -2.24 Mn |
| Mar 31, 2023 | -2.20 Mn |
| Dec 31, 2022 | -5.52 Mn |
| Sep 30, 2022 | -9.90 Mn |
| Jun 30, 2022 | -8.00 Mn |
| Mar 31, 2022 | -1.67 Mn |
| Dec 31, 2021 | -10.84 Mn |
| Sep 30, 2021 | -17.16 Mn |
| Jun 30, 2021 | -935,544.00 |
| Mar 31, 2021 | -907,731.00 |
| Dec 31, 2020 | 213,995.00 |